161 related articles for article (PubMed ID: 27377907)
1. Bone alkaline phosphatase as a surrogate marker of bone metastasis in gastric cancer patients.
Lim SM; Kim YN; Park KH; Kang B; Chon HJ; Kim C; Kim JH; Rha SY
BMC Cancer; 2016 Jul; 16():385. PubMed ID: 27377907
[TBL] [Abstract][Full Text] [Related]
2. The clinical importance of bone metabolic markers in detecting bone metastasis of lung cancer.
Bayrak SB; Ceylan E; Serter M; Karadağ F; Demir E; Çildağ O
Int J Clin Oncol; 2012 Apr; 17(2):112-8. PubMed ID: 21691728
[TBL] [Abstract][Full Text] [Related]
3. Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy.
Tamada T; Sone T; Tomomitsu T; Jo Y; Tanaka H; Fukunaga M
J Bone Miner Metab; 2001; 19(1):45-51. PubMed ID: 11156473
[TBL] [Abstract][Full Text] [Related]
4. Relationship between prostate-specific antigen, clinical stage, and degree of bone metastasis in patients with prostate cancer: comparison with prostatic acid phosphatase and alkaline phosphatase.
Akimoto S; Furuya Y; Akakura K; Shimazaki J; Ito H
Int J Urol; 1997 Nov; 4(6):572-5. PubMed ID: 9477186
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of PSA, ALP, ICTP, and BSP in prostate cancer patients and the significance of ROC curve in the diagnosis of prostate cancer bone metastases.
Wei RJ; Li TY; Yang XC; Jia N; Yang XL; Song HB
Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323113
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment levels of urinary deoxypyridinoline as a potential marker in patients with prostate cancer with or without bone metastasis.
Wymenga LF; Groenier K; Schuurman J; Boomsma JH; Elferink RO; Mensink HJ
BJU Int; 2001 Aug; 88(3):231-5. PubMed ID: 11488735
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of bone markers for detection of bone metastases in lung cancer patients.
Alataş F; Alataş O; Metintaş M; Colak O; Erginel S; Harmanci E
Clin Biochem; 2002 Jun; 35(4):293-6. PubMed ID: 12135691
[TBL] [Abstract][Full Text] [Related]
8. Implications of serum bone turnover markers in prostate cancer patients with bone metastasis.
Kamiya N; Suzuki H; Yano M; Endo T; Takano M; Komaru A; Kawamura K; Sekita N; Imamoto T; Ichikawa T
Urology; 2010 Jun; 75(6):1446-51. PubMed ID: 20206975
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes and prognostic factors for gastric cancer patients with bone metastasis.
Mikami J; Kimura Y; Makari Y; Fujita J; Kishimoto T; Sawada G; Nakahira S; Nakata K; Tsujie M; Ohzato H
World J Surg Oncol; 2017 Jan; 15(1):8. PubMed ID: 28061855
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of serum BAP, TRACP 5b and ICTP as bone metabolic markers for bone metastasis screening in lung cancer patients.
Tang C; Liu Y; Qin H; Li X; Guo W; Li J; Wang W; Qu L; Hu H; Xu C; Zheng L; Huang Y; Liu B; Gao H; Halleen JM; Liu X
Clin Chim Acta; 2013 Nov; 426():102-7. PubMed ID: 24055775
[TBL] [Abstract][Full Text] [Related]
11. A meta-analysis survey of appropriate bone turnover markers in the detection of bone metastasis in lung cancer.
Huang J; Gu T; Ying J
Int J Clin Oncol; 2017 Dec; 22(6):1015-1025. PubMed ID: 28677013
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of serum alkaline phosphatase and lactate dehydrogenase levels in patients with unresectable advanced gastric cancer.
Namikawa T; Ishida N; Tsuda S; Fujisawa K; Munekage E; Iwabu J; Munekage M; Uemura S; Tsujii S; Tamura T; Yatabe T; Maeda H; Kitagawa H; Kobayashi M; Hanazaki K
Gastric Cancer; 2019 Jul; 22(4):684-691. PubMed ID: 30417313
[TBL] [Abstract][Full Text] [Related]
13. [Clinicopathological study of gastric cancer with bone metastasis].
Nishidoi H; Koga S
Gan To Kagaku Ryoho; 1987 May; 14(5 Pt 2):1717-22. PubMed ID: 3592711
[TBL] [Abstract][Full Text] [Related]
14. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
Ozu C; Nakashima J; Horiguchi Y; Oya M; Ohigashi T; Murai M
Int J Urol; 2008 May; 15(5):419-22. PubMed ID: 18452459
[TBL] [Abstract][Full Text] [Related]
15. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
Ebert W; Muley T; Herb KP; Schmidt-Gayk H
Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer.
Chung JH; Park MS; Kim YS; Chang J; Kim JH; Kim SK; Kim SK
Yonsei Med J; 2005 Jun; 46(3):388-93. PubMed ID: 15988811
[TBL] [Abstract][Full Text] [Related]
17. [Clinical usefulness of serum pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP) for diagnosis of bone metastasis in patients with primary lung cancer].
Yokoyama T; Yamamoto M; Shima K; Suzuki K; Sako C; Ito G; Kume M; Maeda M
Nihon Kokyuki Gakkai Zasshi; 2003 Dec; 41(12):857-60. PubMed ID: 14727545
[TBL] [Abstract][Full Text] [Related]
18. [Relationship of serum prostate-specific antigen and alkaline phosphatase levels with bone metastases in patients with prostate cancer].
Wang ZL; Wang XF
Zhonghua Nan Ke Xue; 2005 Nov; 11(11):825-7. PubMed ID: 16333960
[TBL] [Abstract][Full Text] [Related]
19. Metabolic gaps in bone formation may be a novel marker to monitor the osseous metastasis of prostate cancer.
Koizumi M; Yonese J; Fukui I; Ogata E
J Urol; 2002 Apr; 167(4):1863-6. PubMed ID: 11912449
[TBL] [Abstract][Full Text] [Related]
20. Serum calcium, alkaline phosphotase and hemoglobin as risk factors for bone metastases in bladder cancer.
Huang P; Lan M; Peng AF; Yu QF; Chen WZ; Liu ZL; Liu JM; Huang SH
PLoS One; 2017; 12(9):e0183835. PubMed ID: 28902911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
